A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

Completed · Phase 1 · Has a placebo group

Conditions studied: HCV Infection

In brief

The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of ketoconazole on steady state ABT-072 pharmacokinetics.

Key facts

Study ID

NCT00890318

Run by

Abbott

People needed

32

Starts

2009-04-01

Last updated by the study team

2010-10-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Main Selection Criteria for Healthy Volunteers:
• Subject has provided written consent.
• Subject is in general good health.
• If female, subject is postmenopausal for at least 2 years or surgically sterile.
• If female, subject is not pregnant and is not breast-feeding.
• Male or female between 18 and 55 years old, inclusive.
• If male, subject must be surgically sterile or practicing at least 1 method of birth control.
• Body Mass Index (BMI) is 18 to 29, inclusive.

You may not qualify if…

• Use of medications including over the counter and vitamines.
• Abuse of alcohol, drugs, or nicotine.
• Current diseases or disorders.
• History of cardiac disease.
• If after consideration by the investigator, for any reason, that you are unsuitable to receive ABT-072.

Where it is running

• Abbott Clinical Pharmaceutical Research Unit — Waukegan, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.